Balyasny Asset Management
NVO

Balyasny Asset Management’s Novo Nordisk NVO Stock Holding History

Balyasny Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1M Sell
383,146
-124,963
-25% -$5.92M 0.02% 855
2025
Q4 		$25.9M Buy
508,109
+464,129
+1,055% +$23.7M 0.03% 596
2025
Q3 		$2.44M Sell
43,980
-1,490,771
-97% -$87.3M ﹤0.01% 1711
2025
Q2 		$106M Buy
1,534,751
+1,227,342
+399% +$83.5M 0.16% 142
2025
Q1 		$21.3M Sell
307,409
-420,105
-58% -$34.7M 0.04% 571
2024
Q4 		$62.6M Buy
727,514
+202,223
+38% +$21.9M 0.09% 261
2024
Q3 		$62.5M Buy
525,291
+141,647
+37% +$18.9M 0.1% 236
2024
Q2 		$54.8M Buy
+383,644
New +$50.8M 0.1% 272
2024
Q1 		– Sell
-403,673
Closed -$41.8M – 2959
2023
Q4 		$41.8M Buy
+403,673
New +$39.9M 0.08% 315
2023
Q2 		– Sell
-209,098
Closed -$17.1M – 2629
2023
Q1 		$16.6M Buy
+209,098
New +$14.8M 0.04% 584
2021
Q3 		– Sell
-374,192
Closed -$15.7M – 2281
2021
Q2 		$15.7M Buy
+374,192
New +$14.5M 0.07% 365
2020
Q3 		– Sell
-725,616
Closed -$23.8M – 1502
2020
Q2 		$23.8M Sell
725,616
-208,840
-22% -$6.66M 0.21% 132
2020
Q1 		$28.1M Sell
934,456
-459,528
-33% -$13.7M 0.33% 71
2019
Q4 		$40.3M Sell
1,393,984
-475,736
-25% -$13.2M 0.24% 110
2019
Q3 		$48.3M Buy
1,869,720
+1,313,966
+236% +$33.2M 0.33% 64
2019
Q2 		$14.2M Buy
555,754
+289,080
+108% +$7.14M 0.09% 308
2019
Q1 		$6.97M Sell
266,674
-256,526
-49% -$6.3M 0.05% 485
2018
Q4 		$12.1M Sell
523,200
-53,284
-9% -$1.18M 0.09% 310
2018
Q3 		$13.6M Sell
576,484
-198,212
-26% -$4.84M 0.06% 396
2018
Q2 		$17.9M Buy
774,696
+181,136
+31% +$4.3M 0.08% 338
2018
Q1 		$14.6M Buy
+593,560
New +$15.6M 0.06% 409

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Balyasny Asset Management's NVO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Novo Nordisk (NVO) stake by 25% in Q1 2026, selling an estimated $5.92M and leaving 383,146 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #855.

Balyasny Asset Management first reported a position in NVO in Q1 2018 and has held it in 21 quarters since. The position peaked at $106M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Balyasny Asset Management held 383,146 shares of Novo Nordisk worth $14.1M as of Q1 2026.
  • Balyasny Asset Management sold 124,963 Novo Nordisk shares in Q1 2026, an estimated $5.92M.
  • Novo Nordisk made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #855 holding.
  • Balyasny Asset Management first reported a position in Novo Nordisk in Q1 2018 and has held it in 21 quarters since.
  • Balyasny Asset Management's Novo Nordisk position peaked at $106M in Q2 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.